Article
Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome.
Blood cancer journal - 8 Jul 2016
Cher C Y, Leung G M K, Au C H, Chan T L, Ma E S K, Sim J P Y, Gill H, Lie A K W, Liang R, Wong K F, Siu L L P, Tsui C S P, So C C, Wong H W W, Yip S F, Lee H K K, Liu H S Y, Lau J S M, Luk T H, Lau C K, Lin S Y, Kwong Y L, Leung A Y H
Abstract excerpt
Clinical outcome and mutations of 96 core-binding factor acute myeloid leukemia (AML) patients 18-60 years old were examined. Complete remission (CR) after induction was 94.6%. There was no significant difference in CR, leukemia-free-survival (LFS) and overall survival (OS) between t(8;21) (N=67) and inv(16) patients (N=29). Univariate analysis showed hematopoietic stem cell transplantation at CR1 as the only...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.